High HHS FDA

HHS Seeks Input on Regulating Deceased Donor Islet Cells for Type 1 Diabetes Treatment

HHS Request for Information explores whether deceased donor islet cells should be regulated as organs under OPTN policy or as cell products, impacting transplant access and regulatory pathways for Type 1 diabetes therapies. The Department of Health and Human Services (HHS) has opened a public...

The deep analysis — cross-item commentary and how this topic has evolved — is part of SignalHealth Pro.

Start a 14-day Pro trial — $9/month

Sources — verify every claim

Health and Human Services Department, Food and Drug Administration, Health Resources and Services Administration · Improving Patient Access to Deceased Donor Islet Cells and Cell Products; Request for Information · Sep 24

Trust record

Agent curated